FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:529-534 August 21, 1997 Number 8 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Mutations of the p53 gene are associated with a poor prognosis in several types of cancer. We investigated the prognostic importance of p53 mutations in patients with aggressive B-cell lymphoma.

Methods We examined the relation between the presence or absence of a detectable p53 mutation in lymphoma cells and the response to chemotherapy and overall survival in 102 previously untreated patients with aggressive B-cell lymphoma. Mutations of the p53 gene were identified by polymerase-chain-reaction–mediated analysis of single-strand conformation polymorphisms and by direct sequencing.

Results Of 102 cases of aggressive B-cell lymphoma, 22 (22 percent) involved p53 mutations. The rate of complete remission was significantly lower in patients with a tumor carrying a p53 mutation (6 of 22 patients, 27 percent) than in those with the wild-type p53 gene (61 of 80 patients, 76 percent) (P<0.001). Overall survival was significantly lower among patients with p53 mutations than among those with the wild-type p53 gene; the Kaplan–Meier estimates of survival at five years were 16 percent and 64 percent, respectively (P<0.001). Multivariate analysis incorporating prognostic factors from the international prognostic index demonstrated that p53 mutations had independent effects on the rates of complete remission and survival. When we categorized patients according to the international prognostic index, we found no effect of p53 mutations in patients in the groups at high-intermediate and high risk. However, these mutations were significantly associated (P<0.001) with low rates of complete remission (33 percent vs. 91 percent) and survival (27 percent vs. 81 percent at five years) in the groups at low and low-intermediate risk.

Conclusions Mutations of the p53 gene are associated with a poor prognosis in patients with aggressive B-cell lymphoma.

Source Information

From the Department of Hematological Oncology, Gifu Prefectural Tajimi Hospital, Tajimi (A.I.); the First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya (T.K., T.W., H.K., H.N., H.S., T.H.); and the Department of Hematological Oncology, National Nagoya Hospital, Nagoya (K.T.) — all in Japan.

Address reprint requests to Dr. Ichikawa at the Dept. of Hematological Oncology, Gifu Prefectural Tajimi Hospital, Maehata-cho, Tajimi, Japan.

Full Text of this Article

This article has been cited by other articles:

• Coles, A. H., Marfella, C. G.A., Imbalzano, A. N., Steinman, H. A., Garlick, D. S., Gerstein, R. M., Jones, S. N. (2008). p37Ing1b Regulates B-Cell Proliferation and Cooperates with p53 to Suppress Diffuse Large B-Cell Lymphomagenesis. Cancer Res. 68: 8705-8714 [Abstract] [Full Text]  
• Young, K. H., Leroy, K., Moller, M. B., Colleoni, G. W. B., Sanchez-Beato, M., Kerbauy, F. R., Haioun, C., Eickhoff, J. C., Young, A. H., Gaulard, P., Piris, M. A., Oberley, T. D., Rehrauer, W. M., Kahl, B. S., Malter, J. S., Campo, E., Delabie, J., Gascoyne, R. D., Rosenwald, A., Rimsza, L., Huang, J., Braziel, R. M., Jaffe, E. S., Wilson, W. H., Staudt, L. M., Vose, J. M., Chan, W. C., Weisenburger, D. D., Greiner, T. C. (2008). Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 112: 3088-3098 [Abstract] [Full Text]  
• Young, K. H., Weisenburger, D. D., Dave, B. J., Smith, L., Sanger, W., Iqbal, J., Campo, E., Delabie, J., Gascoyne, R. D., Ott, G., Rimsza, L., Muller-Hermelink, H. K., Jaffe, E. S., Rosenwald, A., Staudt, L. M., Chan, W. C., Greiner, T. C. (2007). Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 110: 4396-4405 [Abstract] [Full Text]  
• Lonning, P., Knappskog, S, Staalesen, V, Chrisanthar, R, Lillehaug, J. (2007). Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol 18: 1293-1306 [Abstract] [Full Text]  
• Kaderali, L., Zander, T., Faigle, U., Wolf, J., Schultze, J. L., Schrader, R. (2006). CASPAR: a hierarchical bayesian approach to predict survival times in cancer from gene expression data. Bioinformatics 22: 1495-1502 [Abstract] [Full Text]  
• Lossos, I. S., Morgensztern, D. (2006). Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma. JCO 24: 995-1007 [Abstract] [Full Text]  
• Lossos, I. S. (2005). Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. JCO 23: 6351-6357 [Abstract] [Full Text]  
• Abramson, J. S., Shipp, M. A. (2005). Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 106: 1164-1174 [Abstract] [Full Text]  
• Katahira, T., Takayama, T., Miyanishi, K., Hayashi, T., Ikeda, T., Takahashi, Y., Takimoto, R., Matsunaga, T., Kato, J., Niitsu, Y. (2004). Plasma Glutathione S-Transferase P1-1 as a Prognostic Factor in Patients with Advanced Non-Hodgkin's Lymphoma (Stages III and IV). Clin. Cancer Res. 10: 7934-7940 [Abstract] [Full Text]  
• Bea, S., Colomo, L., Lopez-Guillermo, A., Salaverria, I., Puig, X., Pinyol, M., Rives, S., Montserrat, E., Campo, E. (2004). Clinicopathologic Significance and Prognostic Value of Chromosomal Imbalances in Diffuse Large B-Cell Lymphomas. JCO 22: 3498-3506 [Abstract] [Full Text]  
• Lossos, I. S., Czerwinski, D. K., Alizadeh, A. A., Wechser, M. A., Tibshirani, R., Botstein, D., Levy, R. (2004). Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes. NEJM 350: 1828-1837 [Abstract] [Full Text]  
• Geisler, S., Borresen-Dale, A.-L., Johnsen, H., Aas, T., Geisler, J., Akslen, L. A., Anker, G., Lonning, P. E. (2003). TP53 Gene Mutations Predict the Response to Neoadjuvant Treatment with 5-Fluorouracil and Mitomycin in Locally Advanced Breast Cancer. Clin. Cancer Res. 9: 5582-5588 [Abstract] [Full Text]  
• Little, R. F., Pittaluga, S., Grant, N., Steinberg, S. M., Kavlick, M. F., Mitsuya, H., Franchini, G., Gutierrez, M., Raffeld, M., Jaffe, E. S., Shearer, G., Yarchoan, R., Wilson, W. H. (2003). Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 101: 4653-4659 [Abstract] [Full Text]  
• Sanchez-Beato, M., Sanchez-Aguilera, A., Piris, M. A. (2003). Cell cycle deregulation in B-cell lymphomas. Blood 101: 1220-1235 [Abstract] [Full Text]  
• Leroy, K., Haioun, C., Lepage, E., Le Metayer, N., Berger, F., Labouyrie, E., Meignin, V., Petit, B., Bastard, C., Salles, G., Gisselbrecht, C., Reyes, F., Gaulard, Ph. (2002). p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 13: 1108-1115 [Abstract] [Full Text]  
• Barrans, S. L., Carter, I., Owen, R. G., Davies, F. E., Patmore, R. D., Haynes, A. P., Morgan, G. J., Jack, A. S. (2002). Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99: 1136-1143 [Abstract] [Full Text]  
• Stankovic, T., Stewart, G. S., Fegan, C., Biggs, P., Last, J., Byrd, P. J., Keenan, R. D., Moss, P. A. H., Taylor, A. M. R. (2002). Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 99: 300-309 [Abstract] [Full Text]  
• Latronico, A. C., Pinto, E. M., Domenice, S., Fragoso, M. C. B. V., Martin, R. M., Zerbini, M. C., Lucon, A. M., Mendonca, B. B. (2001). An Inherited Mutation Outside the Highly Conserved DNA-Binding Domain of the p53 Tumor Suppressor Protein in Children and Adults with Sporadic Adrenocortical Tumors. J. Clin. Endocrinol. Metab. 86: 4970-4973 [Abstract] [Full Text]  
• Lossos, I. S., Jones, C. D., Warnke, R., Natkunam, Y., Kaizer, H., Zehnder, J. L., Tibshirani, R., Levy, R. (2001). Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 98: 945-951 [Abstract] [Full Text]  
• Geisler, S., Lønning, P. E., Aas, T., Johnsen, H., Fluge, O., Haugen, D. F., Lillehaug, J. R., Akslen, L. A., Børresen-Dale, A.-L. (2001). Influence of TP53 Gene Alterations and c-erbB-2 Expression on the Response to Treatment with Doxorubicin in Locally Advanced Breast Cancer. Cancer Res. 61: 2505-2512 [Abstract] [Full Text]  
• Niitsu, N., Okabe-Kado, J., Okamoto, M., Takagi, T., Yoshida, T., Aoki, S., Hirano, M., Honma, Y. (2001). Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. Blood 97: 1202-1210 [Abstract] [Full Text]  
• Filipits, M., Jaeger, U., Simonitsch, I., Chizzali-Bonfadin, C., Heinzl, H., Pirker, R. (2000). Clinical Relevance of the Lung Resistance Protein in Diffuse Large B-Cell Lymphomas. Clin. Cancer Res. 6: 3417-3423 [Abstract] [Full Text]  
• Adida, C., Haioun, C., Gaulard, P., Lepage, E., Morel, P., Briere, J., Dombret, H., Reyes, F., Diebold, J., Gisselbrecht, C., Salles, G., Altieri, D. C., Molina, T. J. (2000). Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96: 1921-1925 [Abstract] [Full Text]  
• SCHMITT, C.A., WALLACE-BRODEUR, R.R., ROSENTHAL, C.T., MCCURRACH, M.E., LOWE, S.W. (2000). DNA Damage Responses and Chemosensitivity in the E{micro}-myc Mouse Lymphoma Model. Cold Spring Harb Symp Quant Biol 65: 499-510 [Abstract]  
• Vanasse, G. J., Concannon, P., Willerford, D. M. (1999). Regulated Genomic Instability and Neoplasia in the Lymphoid Lineage. Blood 94: 3997-4010 [Full Text]  
• Niitsu, N., Okabe-Kado, J., Kasukabe, T., Yamamoto-Yamaguchi, Y., Umeda, M., Honma, Y. (1999). Prognostic Implications of the Differentiation Inhibitory Factor nm23-H1 Protein in the Plasma of Aggressive Non-Hodgkin's Lymphoma. Blood 94: 3541-3550 [Abstract] [Full Text]  
• Copie-Bergman, C., Gaulard, P., Maouche-Chretien, L., Briere, J., Haioun, C., Alonso, M. A., Romeo, P.-H., Leroy, K. (1999). The MAL Gene Is Expressed in Primary Mediastinal Large B-Cell Lymphoma. Blood 94: 3567-3575 [Abstract] [Full Text]  
• Schneider-Stock, R., Ziegeler, A., Haeckel, C., Franke, D.-S., Rys, J., Roessner, A. (1999). Prognostic Relevance of p53 Alterations and Mib-1 Proliferation Index in Subgroups of Primary Liposarcomas. Clin. Cancer Res. 5: 2830-2835 [Abstract] [Full Text]  
• Montesinos-Rongen, M., Roers, A., Kuppers, R., Rajewsky, K., Hansmann, M.-L. (1999). Mutation of the p53 Gene Is Not a Typical Feature of Hodgkin and Reed-Sternberg Cells in Hodgkin's Disease. Blood 94: 1755-1760 [Abstract] [Full Text]  
• Kawano, S., Miller, C. W., Gombart, A. F., Bartram, C. R., Matsuo, Y., Asou, H., Sakashita, A., Said, J., Tatsumi, E., Koeffler, H. P. (1999). Loss of p73 Gene Expression in Leukemias/Lymphomas Due to Hypermethylation. Blood 94: 1113-1120 [Abstract] [Full Text]  
• Moller, M. B., Gerdes, A.-M., Skjodt, K., Mortensen, L. S., Pedersen, N. T. (1999). Disrupted p53 Function as Predictor of Treatment Failure and Poor Prognosis in B- and T-Cell Non-Hodgkin's Lymphoma. Clin. Cancer Res. 5: 1085-1091 [Abstract] [Full Text]  
• Drach, J., Ackermann, J., Fritz, E., Kromer, E., Schuster, R., Gisslinger, H., DeSantis, M., Zojer, N., Fiegl, M., Roka, S., Schuster, J., Heinz, R., Ludwig, H., Huber, H. (1998). Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy. Blood 92: 802-809 [Abstract] [Full Text]  
• Nicolaides, C., Dimou, S., Pavlidis, N. (1998). Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas. The Oncologist 3: 189-197 [Abstract] [Full Text]